SI2516406T1 - Mglu2 agonisti - Google Patents
Mglu2 agonistiInfo
- Publication number
- SI2516406T1 SI2516406T1 SI201030387T SI201030387T SI2516406T1 SI 2516406 T1 SI2516406 T1 SI 2516406T1 SI 201030387 T SI201030387 T SI 201030387T SI 201030387 T SI201030387 T SI 201030387T SI 2516406 T1 SI2516406 T1 SI 2516406T1
- Authority
- SI
- Slovenia
- Prior art keywords
- mglu2 agonists
- mglu2
- agonists
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09382290 | 2009-12-21 | ||
US30523910P | 2010-02-17 | 2010-02-17 | |
PCT/US2010/060371 WO2011084437A1 (en) | 2009-12-21 | 2010-12-15 | Mglu2 agonists |
EP10798419.7A EP2516406B1 (en) | 2009-12-21 | 2010-12-15 | Mglu2 agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2516406T1 true SI2516406T1 (sl) | 2013-11-29 |
Family
ID=42026702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201030387T SI2516406T1 (sl) | 2009-12-21 | 2010-12-15 | Mglu2 agonisti |
Country Status (35)
Country | Link |
---|---|
US (1) | US8318184B2 (sl) |
EP (1) | EP2516406B1 (sl) |
JP (1) | JP5779190B2 (sl) |
KR (1) | KR101395356B1 (sl) |
CN (1) | CN102695701B (sl) |
AR (1) | AR079343A1 (sl) |
AU (1) | AU2010340039B2 (sl) |
BR (1) | BR112012017188B1 (sl) |
CA (1) | CA2784667C (sl) |
CR (1) | CR20120322A (sl) |
CY (1) | CY1114880T1 (sl) |
DK (1) | DK2516406T3 (sl) |
DO (1) | DOP2012000173A (sl) |
EA (1) | EA020229B1 (sl) |
EC (1) | ECSP12011989A (sl) |
ES (1) | ES2435651T3 (sl) |
HK (1) | HK1171228A1 (sl) |
HN (1) | HN2012001160A (sl) |
HR (1) | HRP20131052T1 (sl) |
IL (1) | IL220011A (sl) |
JO (1) | JO2978B1 (sl) |
MA (1) | MA33824B1 (sl) |
MX (1) | MX2012007332A (sl) |
MY (1) | MY160618A (sl) |
NZ (1) | NZ600305A (sl) |
PE (1) | PE20121688A1 (sl) |
PL (1) | PL2516406T3 (sl) |
PT (1) | PT2516406E (sl) |
RS (1) | RS53063B (sl) |
SG (1) | SG181836A1 (sl) |
SI (1) | SI2516406T1 (sl) |
TN (1) | TN2012000281A1 (sl) |
TW (1) | TWI477490B (sl) |
UA (1) | UA107684C2 (sl) |
WO (1) | WO2011084437A1 (sl) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2733221T3 (es) | 2010-02-17 | 2019-11-28 | Takeda Pharmaceuticals Co | Compuesto heterocíclico |
TWI520935B (zh) * | 2010-11-18 | 2016-02-11 | 美國禮來大藥廠 | 作為mGluR2/3拮抗劑之4-經取代-3-苯基磺醯基甲基-雙環[3.1.0]己烷化合物 |
MX2013005623A (es) * | 2010-11-18 | 2013-07-05 | Lilly Co Eli | Compuestos de 3-benciloxi-biciclico [3.1.0] hexano 4-sustituidos como antagonistas de mglur 2/3. |
US9296710B2 (en) * | 2011-06-17 | 2016-03-29 | Eli Lilly And Company | Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mGlu2 receptor agonist |
AR089718A1 (es) | 2012-02-01 | 2014-09-10 | Lilly Co Eli | AGONISTAS DE mGlu2/3 |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
KR102461134B1 (ko) * | 2014-01-21 | 2022-10-28 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
UA121965C2 (uk) | 2014-01-21 | 2020-08-25 | Янссен Фармацевтика Нв | Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування |
NZ773901A (en) | 2015-04-01 | 2024-07-26 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5576323A (en) | 1993-12-03 | 1996-11-19 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
US5688826A (en) * | 1995-11-16 | 1997-11-18 | Eli Lilly And Company | Excitatory amino acid derivatives |
GB9605429D0 (en) | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
ZA983930B (en) | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
HUP0400620A3 (en) * | 2001-01-11 | 2012-09-28 | Lilly Co Eli | Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds |
WO2002055485A1 (en) * | 2001-01-11 | 2002-07-18 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
WO2002068380A1 (en) * | 2001-02-22 | 2002-09-06 | Eli Lilly And Company | Synthetic excitatory amino acids |
EP1517915B1 (en) | 2002-06-11 | 2009-01-21 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
JP4984529B2 (ja) * | 2003-06-26 | 2012-07-25 | 大正製薬株式会社 | 2−アミノビシクロ[3.1.0]ヘキサン−2,6−ジカルボン酸誘導体 |
TWI520935B (zh) * | 2010-11-18 | 2016-02-11 | 美國禮來大藥廠 | 作為mGluR2/3拮抗劑之4-經取代-3-苯基磺醯基甲基-雙環[3.1.0]己烷化合物 |
MX2013005623A (es) * | 2010-11-18 | 2013-07-05 | Lilly Co Eli | Compuestos de 3-benciloxi-biciclico [3.1.0] hexano 4-sustituidos como antagonistas de mglur 2/3. |
-
2010
- 2010-12-09 AR ARP100104553A patent/AR079343A1/es active IP Right Grant
- 2010-12-09 JO JO2010439A patent/JO2978B1/en active
- 2010-12-10 TW TW099143362A patent/TWI477490B/zh active
- 2010-12-15 DK DK10798419.7T patent/DK2516406T3/da active
- 2010-12-15 PL PL10798419T patent/PL2516406T3/pl unknown
- 2010-12-15 EP EP10798419.7A patent/EP2516406B1/en active Active
- 2010-12-15 US US12/968,352 patent/US8318184B2/en active Active
- 2010-12-15 NZ NZ600305A patent/NZ600305A/en unknown
- 2010-12-15 SG SG2012045563A patent/SG181836A1/en unknown
- 2010-12-15 MY MYPI2012002794A patent/MY160618A/en unknown
- 2010-12-15 MX MX2012007332A patent/MX2012007332A/es active IP Right Grant
- 2010-12-15 WO PCT/US2010/060371 patent/WO2011084437A1/en active Application Filing
- 2010-12-15 PE PE2012000856A patent/PE20121688A1/es active IP Right Grant
- 2010-12-15 JP JP2012544727A patent/JP5779190B2/ja active Active
- 2010-12-15 BR BR112012017188-7A patent/BR112012017188B1/pt active IP Right Grant
- 2010-12-15 KR KR1020127015935A patent/KR101395356B1/ko active IP Right Grant
- 2010-12-15 UA UAA201206909A patent/UA107684C2/ru unknown
- 2010-12-15 SI SI201030387T patent/SI2516406T1/sl unknown
- 2010-12-15 ES ES10798419T patent/ES2435651T3/es active Active
- 2010-12-15 AU AU2010340039A patent/AU2010340039B2/en active Active
- 2010-12-15 EA EA201290558A patent/EA020229B1/ru not_active IP Right Cessation
- 2010-12-15 PT PT107984197T patent/PT2516406E/pt unknown
- 2010-12-15 RS RS20130530A patent/RS53063B/en unknown
- 2010-12-15 CN CN201080058183.2A patent/CN102695701B/zh active Active
- 2010-12-15 CA CA2784667A patent/CA2784667C/en active Active
-
2012
- 2012-05-24 IL IL220011A patent/IL220011A/en active IP Right Grant
- 2012-05-30 HN HN2012001160A patent/HN2012001160A/es unknown
- 2012-06-01 TN TNP2012000281A patent/TN2012000281A1/en unknown
- 2012-06-13 CR CR20120322A patent/CR20120322A/es unknown
- 2012-06-14 MA MA34967A patent/MA33824B1/fr unknown
- 2012-06-19 DO DO2012000173A patent/DOP2012000173A/es unknown
- 2012-06-20 EC ECSP12011989 patent/ECSP12011989A/es unknown
- 2012-11-23 HK HK12112042.9A patent/HK1171228A1/xx unknown
-
2013
- 2013-11-06 HR HRP20131052AT patent/HRP20131052T1/hr unknown
- 2013-11-14 CY CY20131101012T patent/CY1114880T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0919432D0 (en) | Use | |
IL219073A0 (en) | Combination | |
ZA201702958B (en) | Novel npr-b agonists | |
IL220526A0 (en) | Kokumi-imparting agent | |
EP2478768A4 (en) | ANTIPHYTOVIRAL AGENT | |
HK1171228A1 (en) | Mglu2 agonists mglu2 | |
IL220527A0 (en) | Kokumi-imparting agent | |
EP2407165A4 (en) | ANTIOXIDANTS | |
EP2488184A4 (en) | COMBINATION | |
GB0922505D0 (en) | Use | |
EP2433502A4 (en) | AGENT FOR REMOVING AMERTUME | |
IL218999A0 (en) | Combination | |
IL218797A0 (en) | Combination | |
EP2501379A4 (en) | COMBINATION | |
IL219000A0 (en) | Combination | |
IL218846A0 (en) | Combination | |
PL2427617T3 (pl) | Okucie | |
IL218801A0 (en) | Combination | |
GB0917304D0 (en) | Use | |
GB0909625D0 (en) | Monitors | |
GB0901585D0 (en) | Service Provision | |
GB0912237D0 (en) | Use | |
GB0907472D0 (en) | Use | |
GB0907963D0 (en) | Use | |
GB0919888D0 (en) | Use |